Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?
Ünal D, Eyice-Karabacak D, Kutlu A, Demir S, Tüzer C, Arslan AF, Işık SR, Gelincik A
Allergy · 12 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
- Intake measured by
- Not stated
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2023-08-07 · Allergy · vol. 78 · issue 12 · pp. 3241–3251
- Publisher
- Wiley
- Cited
- 17 citations · more than 90% of similar papers · 2.4× the field average
- References
- 61 works
- Access
- Free to read
- Research areas
- Food Allergy and Anaphylaxis Research · Allergic Rhinitis and Sensitization · Mast cells and histamine
- Keywords
- Medicine, Allergy, Tick, Concomitant, Food allergy, Immunoglobulin E, Anaphylaxis, Adverse effect, Incidence (geometry), Internal medicine, Oral immunotherapy, Gastroenterology, Antibody, Immunology, Veterinary medicine
- MeSH
- animals, cattle, sheep, humans, food hypersensitivity, galactose, immunoglobulin e, allergens, immunotherapy, meat, adult, tick bites, biomarkers, red meat
8 authors
From TR
- Derya ÜnalIstanbul University
- D. Eyice‐KarabacakIstanbul University
- Ali KUTLUOrdu University
- Semra DemirIstanbul University
- Can TüzerIstanbul University
- Ahmet ArslanIstanbul University
Abstract
Background
Oral immunotherapy (OIT) is a promising treatment for food allergies. Our aim was to establish the long-term safety and efficacy of a novel red meat (RM) OIT in galactose-alpha-1,3-galactose (alpha-gal) allergy in adults.
Methods
Out of 20 patients with confirmed RM allergy, five (41.66%) underwent an early OIT, seven (58.33%) underwent a delayed protocol and eight patients who were not desensitized formed the patient control group. 15 and 27 day RM OIT for early-onset and delayed-onset alpha-gal allergy were administered, respectively. Desensitized patients were recommended to continue eating at least 100 g RM every day for 6 months and every other day in the following 6 months. After a year, the consumption was recommended 2/3 times in a week. Patients were followed up with skin tests with commercial beef and lamb extracts, fresh raw/cooked beef and lamb and cetuximab and also with serum alpha-gal specific Immunoglobulin-E (sIgE) in the first and fifth years.
Results
All patients who underwent OIT became tolerant to RM. During the 5 year follow-up, the median alpha-gal sIgE concentration gradually decreased in nine patients who consumed RM uneventfully while remained unchanged in the control group (p = .016). In two patients, rare tick bites acted as inducers of hypersensitivity reactions with concomitant elevation of alpha-gal sIgE concentrations whereas one patient with low follow-up alpha-gal sIgE concentrations consumed RM uneventfully after frequent tick bites.
Conclusions
Our study showed the long-term safety and efficacy of alpha-gal OIT. Additionally, alpha-gal sIgE seems to be a potential biomarker to monitor OIT.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.